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Abstract: The management of patients scheduled for surgery with a coronary stent, and 
  receiving 1 or more antiplatelet drugs, has many controversies. The premature   discontinuation of 
antiplatelet drugs substantially increases the risk of stent thrombosis (ST), myocardial infarction, 
and cardiac death, and surgery under an altered platelet function could also lead to an increased 
risk of bleeding in the perioperative period. Because of the conflict in the   recommendations, this 
article reviews the current antiplatelet protocols after positioning a coronary stent, the   evidence 
of increased risk of ST associated with the withdrawal of antiplatelet drugs and increased 
  bleeding risk associated with its maintenance, the different perioperative antiplatelet protocols 
when patients are scheduled for surgery or need an urgent operation, and the therapeutic options 
if excessive bleeding occurs.
Keywords: stent thrombosis, antiplatelet agents, aspirin, clopidogrel, surgical bleeding, 
  perioperative management
Introduction
Percutaneous coronary interventions (PCIs) and coronary stent placement are now 
frequently and increasingly used. Among coronary stents, drug-eluting stents (DESs) 
seem to have some advantages over bare-metal stents (BMSs), but they need more 
time for complete endothelialization.1–3 As antiplatelet therapy is a key part of the 
  management of all these patients, during the perioperative period, its management is 
one of the most important safety issues and, nowadays, has many controversies.4
First, the withdrawal of antiplatelet agents (APAs) seems to be associated with an 
increased risk of perioperative stent thrombosis (ST), myocardial infarction (MI), and 
death.5,6 Second, surgery under an altered platelet function could lead to an increased 
risk of bleeding, outweighing the benefit of continuous antiaggregation in some pro-
cedures, mainly those performed in a closed space.7,8
Because of the conflict in the recommendations, this article reviews the protocols 
of administration of APAs after the performance of a PCI with a DES placement and 
their management in patients scheduled for elective surgery or need an emergency 
intervention.
Antiplatelet agents
The most commonly used antiplatelet drugs are cyclooxygenase (COX) inhibitors, 
such as aspirin; adenosine diphosphate (ADP) receptor P2Y12 antagonist, such 
as   clopidogrel, ticlopidine, prasugrel; and integrin αIIbβ3 (glycoprotein IIb/IIIa 
[GPIIb/IIIa]) receptor antagonists.9,10Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Aspirin
The prostanoid TXA2 is the main inductor of platelet 
  aggregation and vasoconstriction. That is, the vascular 
prostanoid PGI2 is the main platelet aggregation inhibitor 
and induces an intense vasodilatation effect. The   antiplatelet 
action of aspirin includes the selective blocking of the platelet 
TXA2 synthesis by the irreversible acetylation of the enzyme 
COX-1, whereas COX-2-mediated PGI2 production is 
largely insensitive to low-dose aspirin inhibition.11 The main 
  pharmacokinetic characteristics of aspirin are known for a long 
time. Aspirin, the regular uncoated tablet, is   rapidly absorbed 
in the stomach and upper intestine, reaching peak plasma 
levels at 30–40 minutes after ingestion (oral bioavailability 
40%–50%). Enteric-coated aspirin can take up to 3–4 hours 
to reach peak plasma levels after its administration12 although 
the half-life of aspirin is close to 15–20  minutes because of 
its rapid clearance from the circulation. The mean life span 
of human platelets is approximately 8–10 days due to both 
platelet and megakaryocytes COX-1 inhibition by aspirin. 
However, as about 10%–12% of circulating platelets are 
replaced every 24 hours, complete recovery of platelet aggre-
gation may occur in 50% of cases by day 3 and in 80% of 
cases by day 4.13 The efficacy and safety of low-dose aspirin 
are well documented. Aspirin reduces the risks of stroke and 
composite outcome of stroke or death in patients with prior 
stroke or transient ischemic attack.14 Low doses of aspirin 
decrease the risk of acute MI or death in patients with both 
unstable angina and chronic stable angina, reduce stroke or 
death in patients with transient cerebral ischemia,15–17 prevent 
thrombotic complications in patients with polycythemia 
vera,18 and reduce early occlusion after aortocoronary bypass 
surgery19 and carotid endarterectomy.20
The balance between preventing vascular occlusion and 
causing excess bleeding with aspirin depends critically on the 
absolute thrombotic vs hemorrhagic risk of the patient.9 The 
meta-analyses by Antithrombotic Trialists’   Collaboration 
about the effects of antiplatelet therapy among patients at 
high risk of occlusive vascular disease17 have shown that the 
benefits of aspirin far exceed the bleeding risks. However, 
it is known that some patients under aspirin therapy at usual 
doses (75–150 mg aspirin daily) still fail to have an optimal 
inhibition of thromboxane A2 pathway. These patients with 
such “aspirin resistance” could remain at high thrombotic 
risk with important clinical implications. There is a lack of 
uniformly accepted definition,21 and the exact prevalence 
is unknown but has been suggested to be between 5.5% 
and 60%.22 This phenomenon is important because in 
patients with some comorbidities, such as diabetes mellitus, 
  hypertension, heart failure, inflammatory disorders, which 
may enhance aspirin resistance, the combination therapy, 
rather than aspirin-alone therapy, will be necessary to reach 
optimal antiplatelet inhibition.22
ADP receptor antagonists
The ADP P2Y12 receptor plays a central role in the   formation 
and stabilization of thrombus and is also essential in the 
complete activation of GPIIb/IIIa. Clopidogrel, ticlopidine, 
and prasugrel act as APAs by irreversibly binding to the 
ADP P2Y12 receptor on platelets, subsequently preventing 
ADP-associated platelet aggregation.23
Clopidogrel
Clopidogrel is a parent drug. After oral administration, 
clopidogrel needs to be metabolized in the liver through 
a cytochrome P450 (CYP3A4) to active metabolite SR 
26334.24 Its plasma elimination half-life is approximately 
8 hours. Clopidogrel produces detectable inhibition of 
platelet   aggregation 2 hours after the administration of 
400–600 mg oral doses, and as in the case of aspirin, platelet 
function returns to normal about 7 days after the last dose of 
clopidogrel. The benefits of clopidogrel for patients with an 
increased risk of recurrent ischemic events,17,25 stroke,26 and 
acute coronary syndromes (ACS)27 have been established 
by large, well-conducted randomized clinical trials. As 
aspirin and clopidogrel have different and complementary 
  mechanisms of action, the combination therapy (dual anti-
platelet therapy [DAT]) is more effective in preventing ST 
and in those presenting with ACS, compared with antiplate-
let monotherapy.28,29 The American College of Cardiology/
American Heart Association (ACC/AHA) and the European 
Society of Cardiology (ESC) have published guidelines for 
the use of APAs in patients who undergo PCI.30,31 A current 
antiplatelet protocol in patients with DESs is discussed in 
a separate section of this article. DAT has been associated 
with significantly increased risk for major bleeding in studies 
of more than 1 month duration compared with antiplatelet 
monotherapy.28 Infrequent complications include intracra-
nial hemorrhage (0.4%) and severe neutropenia (0.5%).26
Prasugrel
Prasugrel is the most recently marketed oral thienopyridine 
derivative. The main advantages of prasugrel are that it has a 
faster onset of action (30 minutes) than clopidogrel, and it is 
a more potent P2Y12 receptor antagonist,   leading to higher 
effects of inhibition of platelet aggregation, lesser variability 
of response, and a lower incidence of drug resistance than Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  clopidogrel.32 Prasugrel is indicated for the prevention of 
atherothrombotic events in patients with ACS   undergoing 
PCI.33 In the analysis of the recent TRial to assess   Improvement 
in Therapeutic Outcomes by   optimizing   platelet inhibitioN 
with prasugrel – Thrombolysis In   Myocardial Infarction 38 
(TRITON-TIMI 38) designed to compare clopidogrel with 
prasugrel in patients undergoing PCI, the benefit from the 
intensive platelet inhibitory effects associated with prasugrel 
was more pronounced in patients with high risk (patients 
with ST segment elevation MI (STEMI) and those with dia-
betes).34,35 However, this reduction in thrombotic events was 
associated with a significant increase in the risk of bleeding, 
which overcame the benefit of prasugrel in certain groups.
integrin αiibβ3 (GPiib/iiia) receptor 
antagonists: abciximab, tirofiban,  
and eptifibatide
After recognizing that the interaction between fibrinogen 
and GPIIb/IIIa is the major final step in platelet aggregation, 
this GP became the target of novel antiplatelet drugs, ie, the 
GPIIb/IIIa antagonists, such as abciximab, tirofiban, and 
eptifibatide. These drugs can be used alone or in combination 
with clopidogrel.36
Abciximab
Abciximab is a chimeric Fab fragment of the murine   antihuman 
GPIIb/IIIa. It blocks fibrinogen ligand binding to GPIIb/IIIa. 
After an intravenous (IV) bolus administration, its half-life 
is ,30 minutes. Abciximab (0.25 mg/kg IV bolus dose and 
0.125 µg/kg/min infusion) produces a rapid   inhibition of 
ADP-induced platelet aggregation with peak effects 2 hours 
after bolus administration. After stopping infusion, a gradual 
recovery of platelet function is observed and then returns to 
.50% of baseline in most patients within the first 24 hours, 
and nearly in all patients within the first 48 hours.37 Abciximab 
is recommended as adjunct therapy in PCI. A meta-analysis of 
the 3 major clinical trials38–40 on the use of abciximab in patients 
undergoing PCI showed that abciximab treatment reduced 
the incidence of ischemic events and all-cause mortality.41 
Bleeding and   thrombocytopenia were the 2 most important 
adverse reactions associated with abciximab. Approximately 
1%–2% of patients treated with abciximab have platelet counts 
,50,000/L, but in almost all cases, the thrombocytopenia was 
effectively controlled by stopping the drug administration.42
Tirofiban
Tirofiban is a specific nonpeptide antagonist of GPIIb/IIIa 
receptors derived from tyrosine. Bolus doses of 15 µg/kg 
  followed by tirofiban infusions 0.15 µg/kg/min produced both 
an inhibition of platelet aggregation induced by ADP nearly 
100% and an increase of the bleeding time .30 minutes. 
Recovery of platelet function was achieved .50% within 
4 hours after discontinuing drug infusion.43 Tirofiban is 
effective in patients with unstable angina and non-Q-wave 
MI44 and protects patients undergoing coronary angioplasty 
for ACS.45
Eptifibatide
Eptifibatide is a synthetic heptapeptide with high selectivity 
by GPIIb/IIIa receptor inhibition. Bolus dose of 180 µg/kg 
of eptifibatide followed by 1 µg/kg/min infusion decreases 
  platelet-induced ATP aggregation .95% and increases 
  bleeding time to 22 minutes when compared with control 
values of 7–8 minutes. After stopping eptifibatide infusion, 
platelet   function recovers .50% of baseline aggregation 
within the first 4 hours.46   Eptifibatide reduces the acute 
adverse outcome of patients undergoing PCI,47 and it is also 
beneficial in patients with unstable angina.48 However, a sig-
nificant interindividual variation in the inhibitory responses 
to eptifibatide has been reported.47
Monitoring antiplatelet effect
Tests of platelet function attempt to measure the point 
in the activation process reached by the platelets of an 
individual patient. Possible reasons for measuring platelet 
function in patients include screening, diagnosis, monitor-
ing antiplatelet therapy, monitoring prohemostatic therapy, 
predicting thrombosis, predicting bleeding, and assessing 
stored platelets.49 In the perioperative period, it would be 
helpful to identify patients who are at risk of bleeding 
because of platelet dysfunction related to the administra-
tion of any APA. However, none of these tests has been 
validated for routine clinical practice and for monitoring 
antiplatelet efficiency in perioperative period of coronary 
interventions; the reason could be a lack of standardization, 
poor correlation between various tests, and expensiveness 
of some of them.50
A wide variety of tests are available for the measurement 
of platelet function, and each has its advantages and disad-
vantages. The tests available for assessing platelet function 
can be summarized as follows (Table 1):49,51
•	 Turbidimetric platelet aggregometry could be considered 
the reference assay to diagnose platelet disorders. How-
ever, it needs a platelet-rich, high-volume plasma sample; 
the results are not completely standardized; the laboratory 
procedure is complex; and the test is time consuming.Vascular Health and Risk Management 2010:6
Table 1 Main platelet function test for monitoring aspirin/clopidogrel therapy
Platelet function test for monitoring aspirin Serum thromboxane B2; urinary 11-dehydro 
thromboxane B2; platelet aggregometry 
(turbidimetric); platelet aggregometry 
(impedance); VerifyNow aspirin assay; 
Plateletworks; TeG platelet Mapping system; 
and platelet function analyzer – 100
Platelet function test for monitoring clopidogrel VASP phosphorylation (flow cytometry); platelet 
aggregometry (turbidimetric); platelet aggregometry 
(impedance); VerifyNow P2Y12 assay; Plateletworks; 
and TeG platelet mapping system
Platelet function test for monitoring GP iib/iiia antagonists Platelet aggregometry (turbidimetric); platelet 
aggregometry (impedance); VerifyNow TRAP assay; 
plateletwork; and platelet flow cytometry
Abbreviations: TeG, thrombelastograph; VASP, vasodilator-stimulated phosphoprotein; TRAP, thrombin receptor activating peptide.
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•	 Impedance aggregometry is more physiological than 
the optical one, but it still requires a reasonably high 
sample volume, and this assay is also time consuming 
and expensive.
•	 The platelet function analyzer (PFA-100) explores the 
platelet adhesive capacity, measuring the closure time 
taken for a platelet plug to occlude an aperture in a 
membrane impregnated with collagen and epinephrine or 
ADP.52 Although the test has advantages such as simplic-
ity, rapid readout, low sample volume, no requirement 
for sample preparation, and that aspirin and clopidogrel 
have been shown to prolong this closure time, there is no 
evident correlation between these results and an increased 
perioperative bleeding.
•	 The Plateletworks analyzer measures the percentage of 
aggregation of whole blood before and after exposure 
to ADP. Its results are contradictory when compared 
with optical aggregometry: there is good correlation for 
clopidogrel53 but limited usage for aspirin.54 Then, it needs 
further studies.
•	 Thromboelastography is a whole blood coagulation 
monitor that can demonstrate the alteration of platelet 
aggregation. However, it is unable to detect the specific 
defects that occur with the administration of aspirin or 
clopidogrel.
•	 The Ultegra rapid platelet function assay system (known 
as VerifyNow®) is a whole blood, point-of-care assay that 
incorporates a single-use cartridge with some biochemi-
cal reagents that can detect platelet dysfunction.55 It is a 
simple, true point-of-care device that does not need rapid 
pipetting and requires only a small sample volume. It has 
been proposed to monitor efficacy of aspirin and clopi-
dogrel and to detect the aspirin-resistant population.
•	 Phosphorylation of vasodilator-stimulated phospho-
protein for the measurement of P2Y12 antagonism is 
commercially available as a flow cytometry kit. It is 
dependent on the target of clopidogrel (P2Y12), and it 
needs low sample volume and whole blood assays, but 
the sample preparation is not easy, and it requires a flow 
cytometer and an experienced technician.
Unfortunately, none of these tests has good correlation 
with perioperative bleeding, so they could not predict the 
bleeding tendency in a patient under the effects of aspirin 
or clopidogrel. Further clinical investigations are necessary 
in this field.
Drug-eluting stents
BMSs have been developed to reduce the rate of restenosis 
after angioplasty. However, the restenosis rate remains high, 
existing in .20% of cases, leading to ischemic coronary 
syndromes, or requiring revascularization in .10% of cases. 
Although the BMS virtually eliminates the elastic recoil 
and premature negative remodeling, the proliferation of the 
endothelium is even more important and uncontrolled than 
with angioplasty alone. This concept was the basis for the 
development of DESs. By preventing neointimal hyperplasia, 
the DES has reduced the need for revascularization under 
10%.1,56,57 In brief, a DES is a metal stent, stainless steel or 
cobalt–chromium alloy, coated with a polymer containing 
a drug with antiproliferative properties. There are drugs 
from the limus family (sirolimus or rapamycin, everolimus, 
pimecrolimus, zotarolimus, biolimus, tacrolimus), paclitaxel 
(Taxol®)58(Table 2).
During angioplasty, the atherosclerotic material and 
subendothelial tissue are exposed to the blood stream, 
  initiating the process of thrombus formation and obstruction Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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of the coronary lumen. The metallic surface of the stent is 
an additional thrombogenic stimulus that persists until it is 
covered with endothelium. In the case of BMS, it is expected 
to be coated within 4–8 weeks, whereas in DES, the drug 
not only inhibits cell proliferation but also causes endothelial 
dysfunction and a local inflammatory reaction, impairing the 
normal healing process of an arterial injury; therefore, the 
thrombotic risk may persist even for years.59,60
Current antiplatelet protocols  
in patients with DESs
APA is recommended in the treatment of patients who had 
undergone PCI. After the combination therapy using aspirin 
and clopidogrel was introduced, the incidence of ST was 
reduced to ,1% of the patients,61 and it became unusual after 
the first month in BMS. However, ST may occur months 
to years after the implantation of DES in association with 
premature cessation of APA. The 2007 update of the ACC/
AHA/Society for Cardiovascular Angiography and Interven-
tions (SCAI) 2005 guideline for the use of APA in patients 
who undergo PCI is summarized in Figure 1.62,63
APA before or during PCi
•	 Patients who were already receiving daily long-term 
aspirin therapy should be given 75–325 mg of aspirin 
before PCI (level of evidence: A).
•	 Patients who were not receiving daily long-term aspirin 
therapy should be given 300–325 mg of aspirin at least 
2 hours (preferably 24 hours) before PCI (level of evi-
dence: C).
•	 A clopidogrel loading dose (LD), usually of 600 mg, 
should be administered before or during PCI (level of 
evidence: C).
•	 In patients undergoing PCI after 12–24 hours of 
  fibrinolytic therapy, a clopidogrel oral LD of 300 mg may 
be considered (level of evidence: C).
•	 If clopidogrel is given at the time of PCI, supplementation 
with GPIIb/IIIa receptor antagonists may be beneficial 
(level of evidence: B).
•	 In patients with absolute contraindication to aspirin, a 
single administration of clopidogrel both 300 and 600 mg 
LD at least 6 hours before PCI, supplemented with or 
without GPIIb/IIIa antagonists, at the time of PCI is 
recommended (level of evidence: C).
There is an agreement about the benefit of higher LD of 
clopidogrel in patients undergoing PCI. Several authors have 
analyzed the effects of different LDs (300 or 600 mg) on the 
inhibition of platelet aggregation, myonecrosis (troponin I 
release), and clinical outcomes in patients undergoing PCI. 
Greater dose of clopidogrel has shown an increase of anti-
platelet effect and a significant decrease of major adverse 
cardiac events, in comparison with 300 mg LD, which 
supports a clinical benefit of higher dose of clopidogrel in 
patients subjected to PCI.64,65
APA after PCi
•	 In patients subjected to PCI and with no allergies or 
increased risk of bleeding, aspirin 162–325 mg daily 
should be given for at least 1 month after BMS implanta-
tion, 3 months after sirolimus-eluting stent implantation, 
and 6 months after paclitaxel-eluting stent implantation. 
Afterward, a daily dose of 75–162 mg of aspirin should 
be maintained indefinitely (level of evidence: B).
•	 The use of low-dose aspirin is supported by data from post 
hoc analysis of the Clopidogrel in Unstable angina to pre-
vent Recurrent Events (CURE) study.66 No   differences in 
Table 2 Types of drug-eluting stent by composition
Stent Manufacturer Platform Drug Polymer
Cypher™ Cordis, J&J Stainless steel, tubular Sirolimus Permanent
Taxus™ Boston Scientific Stainless steel, tubular Paclitaxel Permanent
endeavor™ Medtronic Chrome-cobalt, multiple rings Zotarolimus Permanent
Xience V™ Abbott Chrome-cobalt, multiple rings everolimus Permanent
Promus™ Boston Scientific Chrome-cobalt, multiple rings everolimus Permanente
Costar™ Conor Stainless steel, tubular Paclitaxel Biodegradable
Axxion™ Biosensors Stainless steel, tubular Paclitaxel Permanent
Yukon™ Translumina Stainless steel, tubular Sirolimus No polymer
Janus™ Sorin Coating carbon, tubular Tacrolimus No polymer
Coroflex™ Braun Chrome-cobalt, tubular Paclitaxel Permanent
Nobori™ Terumo Stainless steel, multiple rings Biolimus Biodegradable
Adapted from Sierra et al97 with permission.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the efficacy among the 3 aspirin dose groups (,100 mg, 
101–199 mg, and $200 mg) in combination with clopi-
dogrel have been found. However, an increase of major 
bleeding incidence has been reported with the highest 
dose of aspirin either alone or with the combination of 
clopidogrel.67 Therefore, these data suggest an optimal 
daily dosage of aspirin between 75 and 100 mg to mini-
mize bleeding risk (level of evidence: C).
•	 In post-PCI patients receiving a BMS, clopidogrel should 
be given for a minimum of 1 month, whereas it should 
be given only for a minimum of weeks for patients with 
an increased risk of bleeding (level of evidence: B).
•	 In all post-PCI patients with DES and without high risk 
of bleeding, clopidogrel 75 mg daily should be given for 
at least 12 months (level of evidence: B).
These recommendations are based on the antiplatelet regi-
men used in clinical trials conducted to achieve the approval 
of US Food and Drug Administration (low-risk lesions in low-
risk patients). The anticipated times have been taken for the 
predicted metal stent struts adequate endothelialization time, 
which reduces the ST risk efficiently. The effect of continuous 
use of clopidogrel in patients receiving BMS or DES at 6 and 
12 months was analyzed by an observational study including 
3,165 patients. Clopidogrel did not modify the incidence of 
death or MI at 24 months in patients with BMS. However, 
the continuous use of clopidogrel was associated with lower 
rates of death or MI in patients with DES.68 The American 
Heart Association Science Advisory (AHAA) stresses the 
importance of 12 months DAT and provides reports about the 
potential hazards associated with premature discontinuation of 
these drugs, and thus, they recommend that the prolongation 
of clopidogrel therapy beyond 1 year may be considered in 
patients undergoing DES placement (level of evidence: C).
In a recent meta-analysis, a triple therapy (aspirin plus 
thienopyridine plus cilostazol) has been evaluated to know 
the effect of adding cilostazol to a dual antiplatelet regimen 
to prevent stent restenosis.69 The 6-month restenosis rates 
are significantly lower with triple therapy vs DAT, which 
seems a promising way to reduce cardiac events in patients 
with coronary artery stent.
Bleeding and thrombotic risk 
stratification in the perioperative 
period
The perioperative management of APA must be based on 
the optimal assessment of benefit – risk relationship. This 
Aspirin LD 
75–325 mg
(A)
Aspirin daily 
chronic
Yes No
Aspirin LD 300–325 mg 
at least 2 h before PCI
(preferably 24 h)
(C)
Fibrinolytic therapy 
<24 h before
Yes No
Clopidogrel 
LD 300 mg
(C)
Clopidogrel LD 600 mg 
before1 or when 
PCI is performed
(C)
Plus
PCI
Yes No
Aspirin LD 162–325 mg 
at least 1 month
(up to 6 month)2 
and then 
75–162 mg/day indefinitely
(B)   
Aspirin 75–162 mg 
(C)
Stent
BMS DES
Clopidogrel3 75 mg/day 
for at least 1 month
ideally up to 12 months 
(B)  
Clopidogrel3 75 mg/day for 
at least 12 months (B) or
beyond (C)
Plus
(1)   If  aspirin contraindication, clopidogrel LD should  be given at least 6 hr before (C)
(2)   1 month after BMS implantation, 3 months after sirolimus-eluting stent implantation, and 6 months after paclitaxel-eluting stent implantation
(3)   In patients with potential for lethal or catastrophic subacute thrombosis, consider platelet aggregation studies and increase clopidogrel dose to 150 mg/day if 50% inhibition of platelet aggregation 
        is seen (C)
PCI
Elective Not elective
With stent placement is 
reasonable to administer 
a GP IIb/IIIa antagonist 
(B) 
UA/NSTEMI, PCI without clopidogrel 
GP IIb/IIIa antagonist should be given  
(A)
UA/NSTEMI, PCI with clopidogrel  
GP IIb/IIIa antagonist should be given  
(B) 
Plus
STEMI  
GP IIb/IIIa antagonist may be considered  
(C)
Risk of 
bleeding 
Figure 1 The 2007 update on the recommendations of the ACC/AHA/SCAi 2005–2007 last-updated guidelines on use of antiplatelet drugs in patients who undergo PCi.
Note: in parenthesis, the level of evidence is given.
Abbreviations: PCi, percutaneous coronary intervention; LD, loading dose; BMS, bare-metal stent; DeS, drug-eluting stent; UA, unstable angina; NSTeMi, non-ST segment 
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includes the stratification of the perioperative hemorrhagic 
risk   associated with the continuation of APAs throughout 
surgery and the stratification of the thrombotic risk associated 
with the discontinuation of APA (Table 3).7,8,70–72
Bleeding risk
The perioperative risk for hemorrhage depends on the type 
of APA, the monotherapy or combination therapy, and the 
surgical procedures. As a general rule, the risk of bleeding 
probably increases when the patient receives a dual therapy or 
when antiplatelet therapy is associated with an anticoagulant 
drug (heparin, low-molecular-weight heparin, fondaparinux, 
warfarin). When aspirin is given as monotherapy, the surgical 
bleeding and its related complications have been calculated to 
increase by a factor 1.5,73 but it is controversial if this result 
could be extended to all surgical procedures.72 Indeed, the 
evidence on the risk of bleeding in patients under the effect 
of APA is also controversial, and the results of several recent 
studies are not fully conclusive.74
Finally, the increased bleeding risk with aspirin does not 
mean necessarily an increase in mortality or morbidity, an 
increase in transfusion requirements,75 or a worse result in the 
surgical procedure, with the exception of surgery in a closed 
space, and possibly transurethral prostatectomy. Moreover, 
the risk of surgical bleeding is also increased in these patients 
due to DAT. Burger et al73 have demonstrated, through a meta-
analysis of 41 studies involving 49,590 patients undergoing 
different types of noncardiac surgery, that the bleeding risk 
is multiplied by a factor 1.5 when aspirin treatment is con-
tinued. Yet, this is not accompanied by the increased risk of 
major bleeding complications, with the exception of cases 
in which minor bleeding may have catastrophic results, such 
as intracranial surgery. Also prostate surgery, transurethral 
resection, and radical surgery are generally considered high 
risk for bleeding, but in the last few years, the improved 
resection techniques and laparoscopic approach have helped 
to reduce the risk of hemorrhage in these cases.76
There are no randomized controlled studies that   evaluate 
the risk of bleeding when continuing treatment with   clopidogrel 
in noncardiac surgery. In some case series, the continuation of 
clopidogrel in the perioperative period is not associated with 
excessive bleeding.77 With regard to coronary bypass surgery, 
the CURE trial showed no major   bleeding among patients who 
continued clopidogrel   treatment up to 5 days before surgery vs 
patients who discontinued   clopidogrel 5 days or more before 
surgery, without any   difference in mortality.78
In conclusion, in noncardiac surgery, bleeding could be 
considered as a “minor” complication, and severe events are 
more frequently of cardiac origin.
Thrombotic risk
ST is a severe complication that is associated with a high 
incidence of acute MI (22%–90%) and death (30%–45%).79–81 
The current procedure of DAT with aspirin and thienopyri-
dine (usually clopidogrel) has reduced the incidence of ST 
to around 2% in the long term.82,83 According to the time 
elapsed since the stent implantation, ST is considered “early” 
in the first 30 days, “late” from 30 days to 1 year, and “very 
late” after 1 year.84 The first 30 days after stent placement is 
the period of higher risk of thrombosis, with an incidence of 
60%–75% of cases with ST.82 Although early ST is generally 
considered to be related to the procedure, late and very late 
events are less frequent, and discontinuation of antiplatelet 
therapy seems to be an important risk factor.84
Nevertheless, over the past few years, some   observational 
studies found that late and very late DES thromboses occurred 
more frequently than reported in previous   randomized 
  controlled trials, with an increased risk of mortality.85 
Table 3 Proposed stratification of the hemorrhagic risk related with the continuation of antiplatelet agents through the perioperative 
period and the thrombotic risk associated with their discontinuation 
Minor Moderate Major
Hemorrhagic risk
Transfusion usually not needed; minor plastic/ 
general/OS surgery; and biopsies, tooth extraction, 
surgery of the anterior segment of eye
Transfusion usually needed; cardiac 
surgery; major OS/visceral/eNT/urology 
or reconstructive surgery
Possible bleeding in an enclosed space; cranial 
surgery; spinal surgery; surgery of the posterior; 
segment of eye; and transurethral prostatectomy
Thrombotic risk
.6 mo after AMi; CABG; percutaneous 
coronariography; BM;, coronary surgery; 
and CVS (.12 mo if high-risk patient or 
associated complications)
.12 mo after DeS; 6–36 wks after AMi; 
CABG; BMS; and CVS (6–12 mo if high- 
risk patient or associated complications)
,12 mo after DeS; ,6 wks after AMi; CABG; 
BMS; and CVS (,6 mo if high-risk patient or 
associated complications)
Abbreviations: OS, orthopedic surgery; eNT, ear-nose-throat surgery; AMi, acute myocardial infarction, CABG, coronary artery bypass grafting; BMS, bare metal stent, 
DeS, drug-eluting stent; CVS, cerebrovascular stroke.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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It appeared to be related to the premature discontinuation 
of antiplatelet therapy and with the higher use of DESs 
in off-label indication (around 60% of cases in real-world 
  practice).86 Thus, the safety of DES was questioned.
Recent studies with longer follow-up period allow us 
to summarize the current situation. In a recent Swedish 
  observational study of 17,198 patients followed up for 
1–4 years after stent placement, no significant differences 
in the risk of death or MI were found between both types 
of stent, in the case of either on-label or off-label use.87 
Lastly, Kirtane et al88 have published an extensive meta-
analysis of DES vs BMS in on-label and off-label uses. 
They conclude that the use of DES compared with BMS is 
associated with a significant reduction (46%–55%) in target 
vessel   revascularization. These results seem to be consistent 
in demonstrating that DES use is safe for a broad range of 
lesions and patients at various risk levels.
However, there are different time patterns for the ST 
  depending on the type of stent. Although early thrombosis 
is more frequent in BMS, the incidence of late and very late 
thromboses is higher in DESs.82,89 Several studies have   identified 
multiple factors that contribute to ST (Table 4).90 Some scoring 
systems have been recently developed to estimate the risk for ST; 
one of them include 8 significant predictors, with a stratification 
of patients in low, medium, and high risk groups, and has been 
validated using 1-year data from 4,820 patients (Table 5).91
Finally, it is necessary to highlight that because of its 
relation with perioperative period, most authors agree that 
premature discontinuation of DAT was strongly associated 
with ST82,90,92 with a higher risk if clopidogrel is discontinued 
during the first 6 months after stenting. At 12 months, the 
cessation of clopidogrel does not appear to be related with 
a higher risk of ST.93,94
Management of APAs in the 
perioperative period
Around 5% of patients with a coronary stent are   scheduled 
for noncardiac surgery within the first year after stent 
  implantation.94 Perioperative incidence of major adverse 
cardiac events and mortality in noncardiac surgery in these 
patients can reach a rate of 2.5%–21.4% in the case of ST.95 
This increased risk is strongly associated with the time 
elapsed from stenting to surgery and the premature dis-
continuation of DAT. Thus, this risk could be reduced by 
delaying surgery until the prescribed antiplatelet regimen 
is completed.77,96 Abrupt cessation of antiplatelet therapy 
may be followed by an increase of platelet reactivity or 
“rebound” effect in patients on chronic antiplatelet treat-
ment. In   addition, surgery itself creates a thrombogenic 
situation. The endocrine response to surgical stress may 
indirectly contribute to adverse cardiovascular events, such as 
increased vascular reactivity (vasospasm), platelet activation, 
increased clotting factors in plasma, and decreased fibrin-
olysis, in the perioperative period. Then, the risk of cardiac 
event in the perioperative period is not entirely   prevented 
by continued DAT.
The decision to discontinue the antiplatelet therapy 
before surgery should be based on careful cardiovascular and 
thrombotic risk assessment of the patient and on the type of 
surgery and bleeding risk. In patients with coronary stent, it 
is essential to have specific information on the characteristics 
of coronary disease that has led to stent implantation, the date 
of procedure, the type of stent implanted, and the current 
antiplatelet regimen.97
The recommendations about the perioperative man-
agement of antiplatelet therapy in these patients are not 
fully agreed, but they can be summarized as follows 
(Figure 2):7,8,71,96–100
•	 Whenever possible, antiplatelet therapy should be 
  maintained during the high-risk period for as long 
as it is currently recommended: low-dose aspirin 
(75–100 mg) indefinitely, and clopidogrel 75 mg at least 
during 12 months after DES placement. Therefore, if the 
  surgery is likely to cause little or no risk of bleeding, it 
is   recommended to continue the antiplatelet therapy. 
However, regarding elective procedures in which there is 
a significant risk of perioperative bleeding, surgery should 
be delayed until patients have completed the DAT.
Table 4 Risk factors of stent thrombosis 
Procedure-related factors Stent malposition; stent underexpansion; stent length; persistent slow coronary blood flow; 
positive remodeling; and residual arterial dissection
Patient and lesion-related factors Stenting in the setting of an acute coronary syndrome; premature antiplatelet therapy 
discontinuation; no response to aspirin and/or clopidogrel; low ejection fraction; diabetes 
mellitus; advanced age; stenting: bifurcated lesions, long lesions, small vessels, complex lesions; 
and in-stent restenosis
Characteristics of stent-related factors Delayed endothelialization; type of drug, kinetics of drug release; material and designing; 
polymer versus nonpolymer; type of polymer; and hypersensibility to polymerVascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the need to prevent or to treat bleeding, minimizing the risks 
of ischemia and ST, and whether the hemorrhagic risk may 
endanger the vital or functional prognosis of the intervention. 
The following strategies could be considered to decrease the 
consequences of hemorrhage.
Pharmacological treatment
The administration of desmopressin has been suggested to 
reduce excessive bleeding in patients scheduled for cardiac 
surgery under the effects of aspirin. However, consistent 
beneficial effects of this practice cannot be shown in large 
studies, and the drug cannot be recommended for current 
practice as an effective hemostatic agent in patients treated 
with aspirin.104 The use of recombinant factor VII is contro-
versial. It has been included “off-label” in some strategies or 
protocols to control a life-threatening hemorrhage because it 
could reverse the inhibitory effect of clopidogrel,105 but there 
is not enough evidence to support its inclusion as a standard 
recommendation in urgent surgery for patients under the 
effect of an APA.
Platelet transfusion
As there is no drug to directly antagonize the   antiplatelet 
effect of aspirin or clopidogrel, sometimes, platelet 
  transfusion (1 U/5–10 kg) may be needed to stop bleed-
ing.106 Regular prophylactic transfusion of platelets should 
be discouraged and evaluated carefully on a case-by-case 
basis, considering the expected benefit gained from it and the 
possible risks of platelet transfusion. In patients who have 
received clopidogrel, despite the low immediate hemostatic 
effect, the preoperative transfusion of platelets could be a 
good alternative to facilitate postoperative hemostasis, only 
if the patients undergo surgery with high bleeding risk.52,107
The dilemma of whether to transfuse platelets before the 
beginning of clinical bleeding or only with the aim of treating 
a clinically significant hemostatic alteration depends in most 
cases on the kind of surgery and if the inherent bleeding could 
have a bad vital or functional implication.
Semiurgent surgery
What to do if surgery cannot be delayed and the patient is in 
a high-risk period for thrombosis? The management of APA 
should have minimizing the ST risk as priority, trying to expose 
the patient to the minimal bleeding risk. Several   protocols have 
been proposed with a multidisciplinary approach, although 
none of them has been completely validated:9,106
•	 Low bleeding risk: The recommendation is to maintain 
dual therapy until the day before surgery.
Table 5 Clinical risk score for prediction of stent thrombosis 
and risk stratification as developed by Baran et al91
Clinical factors Hazard ratio Weight
Thienopyridine discontinuation ,6 mo 5.28 5
insulin treated diabetes 4.74 5
Left main stenting 2.73 3
Smoking status 2.63 3
Lesion length .28 mm 2.35 2
Multiple stenting 2.25 2
Moderate to severe lesion calcification 2.25 2
Reference vessel diameter ,3 mm 1.72 2
Total possible score 24
Risk stratification
  Low (ST rate%) 0–6 (0.8)
  Moderate (ST rate%) 7–13 (3.6)
  High (ST rate%) 14–24 (12.6)
Abbreviation: ST, stent thrombosis.
•	 In all cases, it is recommended that a low-dose aspirin 
(75–100 mg) is maintained throughout the perioperative 
period, unless the risk of bleeding clearly outweighs throm-
botic risk. To reduce the potential risk of bleeding, aspirin 
dose .200 mg should be replaced by 75 or 100 mg.
•	 The treatment should be substituted by low-dose   aspirin 
in the case of patients treated with clopidogrel as 
  monotherapy, and where discontinuation is mandatory 
(unless contraindicated).
•	 If antiplatelet therapy must be discontinued, it should be 
stopped the shortest time possible: 2 days for aspirin and 
5 days for clopidogrel. Thereafter, treatment should be 
restarted as soon as possible following surgery after ensuring 
hemostasis, between 6 and 48 hours during the postoperative 
period. Depending on the withdrawal time and to accelerate 
antiplatelet response, LD administration may be indicated 
as follows: aspirin 250 mg, clopidogrel 300 mg.
Protocols involving the use of short-acting substances, 
such as IV administration unfractioned heparin and the 
  infusion of either epifibatide or tirofiban, have been proposed 
to act as a bridge when the discontinuation of clopidogrel 
and/or aspirin is mandatory. It should be started 3 days before 
surgery and stopped 4–8 hours before surgery.101,102 However, 
currently there is no enough evidence to recommend their 
use.71 Some authors defend that if aspirin is maintained, the 
short-term discontinuation of clopidogrel may be relatively 
safe without bridge therapy.103
Management of the APAs  
in cases of emergency surgery
In the patients under the effect of any APA and undergoing 
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•	 Moderate bleeding risk: Aspirin should be continued, and 
clopidogrel should be stopped 5 days before surgery. Some 
authors have proposed a bridging therapy, with the infusion 
of tirofiban and unfractionated heparin started 3 days before 
surgery and maintained until 6 hours before surgery, mainly 
if the patient has additional risk factors and very high throm-
botic risk of DES,101 or the infusion of tirofiban only started 
4 days before surgery until 4 hours before surgery.108
•	 High bleeding risk: Aspirin and clopidogrel should be 
discontinued 5 days before surgery (considered to be the 
best option), or aspirin and clopidogrel should be stopped 
10 days before surgery and a bridging therapy should be 
started as explained earlier.
Conclusions
Surgery after coronary stent placement is associated with a 
moderate to high risk of major adverse cardiac events, mostly 
caused by in-stent thrombosis due to the prothrombotic and 
proinflammatory states, which lead to   hypercoagulability 
  associated with surgical intervention. The interruption 
of antiplatelet therapy before surgery and/or through the 
  perioperative period could have a rebound effect with an 
increase in the hypercoagulation and prothrombotic state 
and more risk for ST.
On the other hand, the maintenance of APA could increase 
the risk of bleeding in some interventions, with a wide range 
of implications: from no influence in the development of 
surgery and outcome to a vital risk associated with bleeding 
in closed spaces. So, the challenge for the surgical team is to 
use a therapy that can minimize both thrombotic and hemor-
rhagic risks to reach the better benefit for the patient.
Although there is no valid algorithm for all situations, 
current trend is to delay all surgery that is not life-threatening 
if the stent has high thrombotic risk and, if not possible, to 
give optimal protection to the patients with BMS or DES with 
the maintenance of at least an APA, or running an alternative 
protocol with anticoagulants and aspirin. In all other patients, 
aspirin should be maintained throughout the perioperative 
period if possible, balancing individual benefit/risk ratio of 
the withdrawal of APA.
Perioperative management of antiplatelet therapy in patients with coronary drug eluting stent (DES) 
Bleeding risk of surgery 
Moderate  Low
Elective Surgery can be deferred? 
Yes 
DES implanted <12 months 
Postpone surgery 
 until >12 month 
after DES 
implantation
Multidisciplinary Consultation: 
Anesthetist + Surgeon + Cardiologist + Hematologist 
Time elapsed from DES implantation 
DES ¥6 months  
SURGERY
DES <6 months 
Maintain dual 
antiplatelet therapy 
High
Evaluation DES thrombosis risk (Table 4) 
• Replace aspirin dose >200 mg by §100 mg
• Maintain aspirin dose §100 mg 
• Stop clopidogrel 5 days  
vs 
• Stop clopidogrel ¥5 days ± bridge therapy
• If necessary stop aspirin 2–5 days ±
bridge therapy 
Stop clopidogrel 5 days  
maintain aspirin 
DES implanted ¥12 months
No
• Replace aspirin dose >200 mg by §100 mg 
• Maintain aspirin dose §100 mg  
• Stop clopidogrel ¥5 days + substitution by
aspirin 100 mg (unless contraindication) 
•  High risk bleeding: stop aspirin 2–5 days
Restart treatment
6–48 hours 
after surgery 
Figure 2 Perioperative management of antiplatelet therapy in patients with drug-eluting stents (DeS).Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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